Cardiovascular and Metabolic Diseases

Cardiovascular and metabolic diseases are a major threat to life for adults, accounting for millions of deaths worldwide each year. We want to develop innovative healthcare solutions that will significantly improve the outcome for patients.

• Heart disease is the number one killer in both men and women worldwide.[1]

• Diabetes is the seventh leading cause of death in the world.[1]

• Retinal diseases threaten the eyesight of millions worldwide.[2]

As part of our long-standing commitment, and propelled by our successes in treating type 2 diabetes and thrombosis, we are advancing different therapies that prevent and treat life-threatening cardiovascular, metabolic and retinal diseases.

These diseases are growing, straining patients, their families and healthcare systems. Uncovering new therapies that can improve the quality of life for such a large segment of the population is an important endeavour – one which Janssen CVM will continue to lead in the years to come. Our relentless pursuit of innovation across all stages of drug development means patients get the treatments they need, as fast as possible.[3]

Our mission is global, local and personal: to reshape the future of cardiovascular, metabolic and retinal disease prevention and treatment.

[1]  World Health Organisation. The top 10 causes of death. Available: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed: December 2020.
[2]  Wan Ling Wong, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. 2014 The Lancet Global Health; 2(2):e106-e116.
[3] Janssen. Cardiovascular & Metabolism. Available: https://www.janssen.com/cardiovascular-and-metabolism/about. Accessed: December 2020.

CP-346519 | September 2022